Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,096 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, Wang MC, Park S, Eom KS, Oritani K, Okamoto S, Tauchi T, Kim JS, Zhou D, Saito S, Li J, Handa H, Jianyong L, Ohishi K, Hou M, Depei W, Takenaka K, Liu T, Hu Y, Amagasaki T, Ito K, Gopalakrishna P, Akashi K. Jung CW, et al. Among authors: okamoto s. Leuk Lymphoma. 2015 Jul;56(7):2067-74. doi: 10.3109/10428194.2014.969260. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25315076 Clinical Trial.
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T. Usuki K, et al. Among authors: okamoto s. Int J Hematol. 2012 Apr;95(4):409-19. doi: 10.1007/s12185-012-1026-9. Epub 2012 Feb 23. Int J Hematol. 2012. PMID: 22359103 Clinical Trial.
Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.
Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H, Amagasaki T, Wakase S, Shimozuma K, Akashi K. Oritani K, et al. Among authors: okamoto s. Curr Med Res Opin. 2018 Mar;34(3):531-537. doi: 10.1080/03007995.2017.1415874. Epub 2018 Jan 4. Curr Med Res Opin. 2018. PMID: 29224367
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, Yu J, Mujeebuddin A, Nishimura JI, Lee JW, Peffault de Latour R; 301/302 Study Group. Kulasekararaj AG, et al. Eur J Haematol. 2022 Sep;109(3):205-214. doi: 10.1111/ejh.13783. Epub 2022 Jun 16. Eur J Haematol. 2022. PMID: 35502600 Free PMC article. Clinical Trial.
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; TARGET Investigators. Tauchi T, et al. Among authors: okamoto s. Leuk Res. 2011 May;35(5):585-90. doi: 10.1016/j.leukres.2010.10.027. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145591
3,096 results